My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Y-mAbs Therapeutics, Inc. - Common Stock (NQ:YMAB)

8.610 UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Y-mAbs Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023 ↗

May 10, 2023

Via Benzinga

Earnings Scheduled For May 8, 2023 ↗

May 08, 2023

Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.

Via Benzinga

Preview: Y-mAbs Therapeutics's Earnings ↗

May 05, 2023

Via Benzinga

Earnings Outlook For Y-mAbs Therapeutics ↗

March 29, 2023

Via Benzinga

The Latest Analyst Ratings for Y-mAbs Therapeutics ↗

January 27, 2023

Via Benzinga

Analyst Ratings for Y-mAbs Therapeutics ↗

December 02, 2022

Via Benzinga

Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 09, 2023

Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023 ↗

April 03, 2023

Via Benzinga

Analysts Slash Y-mAbs Therapeutics Price Targets As Uncertainty Looms Over Neuroblastoma Hopeful ↗

October 31, 2022

Via Benzinga

Crude Oil Rises 1.5%; Checkpoint Therapeutics Shares Slide ↗

March 31, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones jumping more than 200 points on Friday. The Dow traded up 0.72% to 33,095.32 while the NASDAQ rose 1.09% to 12,144.31. The S&P...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 31, 2023

Via Benzinga

Quarterly Gain Still Eludes Dow Despite Triple-Digit Lead ↗

March 31, 2023

The Dow Jones Industrial Average is boasting a triple-digit lead this afternoon, as investors unpack this morning's flood of inflation data.

Via Talk Markets

Nasdaq Surges Over 100 Points; G Medical Innovations Shares Plunge ↗

March 31, 2023

U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 100 points on Friday. The Dow traded up 0.69% to 33,086.43 while the NASDAQ rose 1.01% to 12,134.43. The...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 31, 2023

Via Benzinga

Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 31, 2023

Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter.

Via Benzinga

Why Chicken Soup for the Soul Entertainment Shares Are Trading Lower By 30%; Here Are 20 Stocks Moving Premarket ↗

March 31, 2023

Gainers Ault Alliance, Inc. (NASDAQ: AULT) jumped 34.8% to $0.1265 in pre-market trading. Ault Alliance plans share buyback of up to 333.33 million shares of common stock at $0.15 per share through...

Via Benzinga

Earnings Scheduled For March 30, 2023 ↗

March 30, 2023

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 ↗

January 27, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

March 24, 2023

On Friday, 469 companies hit new 52-week lows.

Via Benzinga

Y-mAbs Therapeutics Plans To Deprioritize Omburtamab For Pediatric Cancer, Cuts One Third Of Workforce ↗

January 05, 2023

Via Benzinga

Looking Into Y-mAbs Therapeutics's Recent Short Interest ↗

November 10, 2022

Y-mAbs Therapeutics's (NASDAQ:YMAB) short percent of float has fallen 16.88% since its last report. The company recently reported that it has 3.08 million shares sold short, which is 8.47% of all...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 08, 2022

Gainers

Via Benzinga

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday ↗

November 09, 2022

Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.

Via Benzinga

Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session ↗

November 08, 2022

Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

November 01, 2022

On Tuesday, 85 stocks hit new 52-week lows.

Via Benzinga

ON Semiconductor, Global Payments And Other Big Losers From Monday ↗

November 01, 2022

U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session.

Via Benzinga

S&P 500 Down 0.5%; Crude Oil Falls Sharply ↗

October 31, 2022

U.S. stocks traded lower toward the end of trading, with the S&P 500 dropping around 0.5% on Monday.

Via Benzinga

Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday ↗

November 01, 2022

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.